These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30249195)

  • 1. Clinical trial protocol of the ASTER trial: a double-blind, randomized, placebo-controlled phase III trial evaluating the use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms.
    Tikk K; Czock D; Haefeli WE; Kopp-Schneider A; Brenner H
    BMC Cancer; 2018 Sep; 18(1):914. PubMed ID: 30249195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
    Brenner H; Calderazzo S; Seufferlein T; Ludwig L; Dikopoulos N; Mangold J; Böck W; Stolz T; Eisenbach T; Block T; Kopp-Schneider A; Czock D; Tikk K
    JAMA; 2019 May; 321(17):1686-1692. PubMed ID: 31063574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose aspirin use and performance of immunochemical fecal occult blood tests.
    Brenner H; Tao S; Haug U
    JAMA; 2010 Dec; 304(22):2513-20. PubMed ID: 21139112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Well adjusted qualitative immunochemical faecal occult blood tests could be a promising alternative for inexpensive, high-quality colorectal cancer screening.
    Tao S; Brenner H
    Eur J Cancer Prev; 2013 Jul; 22(4):305-10. PubMed ID: 23702679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design.
    Juul JS; Bro F; Hornung N; Andersen BS; Laurberg S; Olesen F; Vedsted P
    BMC Cancer; 2016 Jul; 16():445. PubMed ID: 27400657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of One-off Flexible Sigmoidoscopy with Fecal Immunochemical Testing in a Large Screening Population.
    Niedermaier T; Weigl K; Hoffmeister M; Brenner H
    Epidemiology; 2018 May; 29(3):397-406. PubMed ID: 29287053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical and guaiac-based fecal occult blood tests for colorectal cancer screening.
    Launois R; Le Moine JG; Uzzan B; Fiestas Navarrete LI; Benamouzig R
    Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):978-89. PubMed ID: 25072382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy.
    Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H
    Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of personalised risk information compared to a positive/negative result on informed choice and intention to undergo colonoscopy following colorectal Cancer screening in Scotland (PERICCS) - a randomised controlled trial: study protocol.
    Steele RJC; Digby J; Chambers JA; O'Carroll RE
    BMC Public Health; 2019 Apr; 19(1):411. PubMed ID: 30991987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal cancer screening using a stool DNA-based SDC2 methylation test: a multicenter, prospective trial.
    Kim CW; Kim H; Kim HR; Kye BH; Kim HJ; Min BS; Oh TJ; An S; Lee SH
    BMC Gastroenterol; 2021 Apr; 21(1):173. PubMed ID: 33858326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
    Oono Y; Iriguchi Y; Doi Y; Tomino Y; Kishi D; Oda J; Takayanagi S; Mizutani M; Fujisaki T; Yamamura A; Hosoi T; Taguchi H; Kosaka M; Delgado P
    Clin Chim Acta; 2010 Jun; 411(11-12):802-5. PubMed ID: 20184867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for colorectal cancer by immunochemical fecal occult blood testing.
    Saito H
    Jpn J Cancer Res; 1996 Oct; 87(10):1011-24. PubMed ID: 8957057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
    Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
    Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Alternative Offers of Screening Sigmoidoscopy and Colonoscopy on Utilization and Yield of Endoscopic Screening for Colorectal Neoplasms: Protocol of the DARIO Randomized Trial.
    Schrotz-King P; Hoffmeister M; Sauer P; Schaible A; Brenner H
    JMIR Res Protoc; 2020 Aug; 9(8):e17516. PubMed ID: 32755890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design.
    Rigter LS; Spaander MC; Moons LM; Bisseling TM; Aleman BM; de Boer JP; Lugtenburg PJ; Janus CP; Petersen EJ; Roesink JM; Raemaekers JM; van der Maazen RW; Cats A; Bleiker EM; Snaebjornsson P; Carvalho B; Lansdorp-Vogelaar I; Jóźwiak K; Te Riele H; Meijer GA; van Leeuwen FE; van Leerdam ME
    BMC Cancer; 2017 Feb; 17(1):112. PubMed ID: 28173773
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.